| pubmed-article:19147520 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19147520 | lifeskim:mentions | umls-concept:C0010823 | lld:lifeskim |
| pubmed-article:19147520 | lifeskim:mentions | umls-concept:C0010825 | lld:lifeskim |
| pubmed-article:19147520 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19147520 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:19147520 | lifeskim:mentions | umls-concept:C0909381 | lld:lifeskim |
| pubmed-article:19147520 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19147520 | pubmed:dateCreated | 2009-2-12 | lld:pubmed |
| pubmed-article:19147520 | pubmed:abstractText | Valganciclovir is a well established drug for the management of cytomegalovirus (CMV) infection in haematopoietic stem cell transplantation (HSCT). Data concerning its safety regarding the development of drug resistance are required. The aim of the present study was to retrospectively investigate CMV drug resistance in a group of HSCT patients experiencing relapses of CMV infection after a first-line pre-emptive antiviral therapy. | lld:pubmed |
| pubmed-article:19147520 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19147520 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19147520 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19147520 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19147520 | pubmed:issn | 1460-2091 | lld:pubmed |
| pubmed-article:19147520 | pubmed:author | pubmed-author:LocatelliFran... | lld:pubmed |
| pubmed-article:19147520 | pubmed:author | pubmed-author:FaldaMicheleM | lld:pubmed |
| pubmed-article:19147520 | pubmed:author | pubmed-author:GhisettiValer... | lld:pubmed |
| pubmed-article:19147520 | pubmed:author | pubmed-author:BuscaAlessand... | lld:pubmed |
| pubmed-article:19147520 | pubmed:author | pubmed-author:PittalugaFabr... | lld:pubmed |
| pubmed-article:19147520 | pubmed:author | pubmed-author:AlliceTiziano... | lld:pubmed |
| pubmed-article:19147520 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19147520 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:19147520 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19147520 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19147520 | pubmed:pagination | 600-8 | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:meshHeading | pubmed-meshheading:19147520... | lld:pubmed |
| pubmed-article:19147520 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19147520 | pubmed:articleTitle | Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. | lld:pubmed |
| pubmed-article:19147520 | pubmed:affiliation | Department of Infectious Disease, Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Turin, Italy. | lld:pubmed |
| pubmed-article:19147520 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19147520 | pubmed:publicationType | Comparative Study | lld:pubmed |
